Global Brain has invested in FullStem Co., Ltd., a company striving to commercialize the high-density large-scale culture technology for stem cells

Global Brain has invested in FullStem Co., Ltd. (FullStem), a company striving to commercialize the high-density large-scale culture technology for stem cells, through its 321FORCE Global Innovation Fund L.P. (321FORCE™).

FullStem is a biotech company aiming to commercialize the stem cell culture technology with the concept of “safe and user-friendly for everyone.” The company is developing a high-density large-scale culture device for stem cells “Achieva-CS,” which implements its proprietary technology of high-density three-dimensional large-scale culture method and recovery method. “Achieva-CS” realizes high-density and space-saving cultivation area by using unique non-woven fabric as the scaffold for cell culture, enabling large-scale culture of stem cells at low cost and in a state close to in vivo environment. The company not only sells “Achieva-CS” but also develops and sells a therapeutic large-scale culture system utilizing this technology.

Global Brain has decided to invest in FullStem, based on its high regard for FullStem’s business and talented management team with the ability to bring its plans to fruition. Global Brain will contribute to the growth of FullStem’s business in collaboration with Mitsui Chemicals, Inc.